8-K
filed January 30, 2024, 6:59 PM ET
ticker RCUS
CIK 0001724521
other material
confidence high
sentiment positive
materiality 0.75
Gilead invests $320M in Arcus at $21/share; collaboration amended to accelerate anti-TIGIT program
Arcus Biosciences, Inc.
- Gilead purchases 15.2M shares for $320M at $21/share, increasing ownership to 33%.
- Collaboration reprioritized: focus on Phase 3 STAR-121 (lung) and STAR-221 (GI); ARC-10 discontinued.
- New Phase 3 STAR-131 registrational study for domvanalimab + zimberelimab in lung cancer planned.
- Johanna Mercier (Gilead CCO) appointed to Arcus board; two prior Gilead designees resign.
- Quemliclustat pancreatic cancer study becomes Arcus-independent; cash runway extended into 2027.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Johanna Mercier was appointed as Class II Director at Arcus Biosciences, Inc..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
the Board appointed Johanna Mercier to the Board as a Class II director
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Ms. Jarrett resigned as Director at Arcus Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Dr. Jaen and Ms. Jarrett resigned from the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Dr. Jaen resigned as Director at Arcus Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Dr. Jaen and Ms. Jarrett resigned from the Board
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcus Biosciences, Inc. entered into Third Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2024-01-29).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Gilead Sciences, Inc.
- Effective
- 2024-01-29
Exact text from the filing
On January 29, 2024, Arcus Biosciences, Inc. (the “Company”) and Gilead Sciences, Inc. (“Gilead”) entered into a Third Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Second Amended & Restated Common Stock Purchase Agreement dated June 27, 2023 (the “Existing Purchase Agreement”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Arcus Biosciences, Inc. amended Amendment No. 3 with Gilead Sciences, Inc. (effective 2024-01-29).
- Action
- amendment
- Agreement
- license
- Counterparty
- Gilead Sciences, Inc.
- Effective
- 2024-01-29
Exact text from the filing
On January 29, 2024, the Company and Gilead also entered into Amendment No. 3 (“Amendment No. 3”) to the Option, License and Collaboration Agreement, dated May 27, 2020, as amended on November 17, 2021 and May 12, 2023 (as previously amended, the “OLCA”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.